Avaliação clinica de doentes hipercolesterolemicos e arteriopatas apos tratamento medico com base na qualidade de vida
AUTOR(ES)
Carla Aparecida Faccio Bosnardo
DATA DE PUBLICAÇÃO
2002
RESUMO
Since atheroesclerosis hits around 10% of the world population and is one of the major causes of death or physical disability in developed countries, endless treatments have been proposed for its control as well as for the treatment of its further complications, such as the chronic occlusive disease of the lower members. The present study was conducted taking this into account. In the period ofMay to December 1999, thirty patients19 men (63,3%) and 11 women (36,6%) of an average age of 59,9 years - were followed up. They were randomly divided into three groups. All patients were arteriopatas and limping. Each group received a different kind of treatment: the first one was treated with a hipocolesterolemic diet and programmed physiotherapy; the second with a normocolesterolemic diet, programmed physiotherapy and a daily dose of 10 mg of Sinvastatine and the third with a ffee diet, programmed physiotherapy and a daily dose of 10 mg of Sinvastatine. A questionnaire about the qua1ity of life was given to each patient, the conc1usion being that the second group was the one with the best response to its treatment, having the greatest improvement regarding quality of life
ASSUNTO(S)
claudicação intermitente qualidade de vida hipercolesterolemia
ACESSO AO ARTIGO
http://libdigi.unicamp.br/document/?code=vtls000253645Documentos Relacionados
- Avaliacao da qualidade do atendimento medico na pratica clinica
- Avaliação clínica e da qualidade de vida de indivíduos com disfunção temporomandibular
- Avaliação da qualidade de vida antes e após simpatectomia por vídeotoracoscopia para tratamento de hiperidrose primária
- Mortalidade, perda de peso e qualidade de vida em pacientes com obesidade mórbida: avaliação do tratamento cirúrgico e clínico após 2 anos
- Exacerbação de doença pulmonar obstrutiva crônica na unidade de terapia intensiva: avaliação clínica, funcional e da qualidade de vida na alta e após 3 meses de seguimento